360 related articles for article (PubMed ID: 26667491)
21. Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy.
Tan AT; Yang N; Lee Krishnamoorthy T; Oei V; Chua A; Zhao X; Tan HS; Chia A; Le Bert N; Low D; Tan HK; Kumar R; Irani FG; Ho ZZ; Zhang Q; Guccione E; Wai LE; Koh S; Hwang W; Chow WC; Bertoletti A
Gastroenterology; 2019 May; 156(6):1862-1876.e9. PubMed ID: 30711630
[TBL] [Abstract][Full Text] [Related]
22. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice.
Lyman MA; Nugent CT; Marquardt KL; Biggs JA; Pamer EG; Sherman LA
J Immunol; 2005 Mar; 174(5):2563-72. PubMed ID: 15728462
[TBL] [Abstract][Full Text] [Related]
23. Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy.
Hinrichs CS
Clin Cancer Res; 2016 Apr; 22(7):1559-64. PubMed ID: 27037253
[TBL] [Abstract][Full Text] [Related]
24. Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers.
Zhang H; Liu L; Zhang J; Chen J; Ye J; Shukla S; Qiao J; Zhan X; Chen H; Wu CJ; Fu YX; Li B
Clin Cancer Res; 2020 Mar; 26(6):1359-1371. PubMed ID: 31831563
[TBL] [Abstract][Full Text] [Related]
25. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.
Otahal P; Hutchinson SC; Mylin LM; Tevethia MJ; Tevethia SS; Schell TD
J Immunol; 2005 Jul; 175(2):700-12. PubMed ID: 16002665
[TBL] [Abstract][Full Text] [Related]
26. Spleen cells from young but not old immunized mice eradicate large established cancers.
Schreiber K; Arina A; Engels B; Spiotto MT; Sidney J; Sette A; Karrison TG; Weichselbaum RR; Rowley DA; Schreiber H
Clin Cancer Res; 2012 May; 18(9):2526-33. PubMed ID: 22415314
[TBL] [Abstract][Full Text] [Related]
27. Optimizing T-cell receptor avidity with somatic hypermutation.
Bassan D; Gozlan YM; Sharbi-Yunger A; Tzehoval E; Eisenbach L
Int J Cancer; 2019 Nov; 145(10):2816-2826. PubMed ID: 31381134
[TBL] [Abstract][Full Text] [Related]
28. The Anticancer Potential of T Cell Receptor-Engineered T Cells.
Ecsedi M; McAfee MS; Chapuis AG
Trends Cancer; 2021 Jan; 7(1):48-56. PubMed ID: 32988787
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity.
Wilde S; Sommermeyer D; Frankenberger B; Schiemann M; Milosevic S; Spranger S; Pohla H; Uckert W; Busch DH; Schendel DJ
Blood; 2009 Sep; 114(10):2131-9. PubMed ID: 19587379
[TBL] [Abstract][Full Text] [Related]
30. T-cell Responses to
Deniger DC; Pasetto A; Robbins PF; Gartner JJ; Prickett TD; Paria BC; Malekzadeh P; Jia L; Yossef R; Langhan MM; Wunderlich JR; Danforth DN; Somerville RPT; Rosenberg SA
Clin Cancer Res; 2018 Nov; 24(22):5562-5573. PubMed ID: 29853601
[No Abstract] [Full Text] [Related]
31. Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.
Raman MC; Rizkallah PJ; Simmons R; Donnellan Z; Dukes J; Bossi G; Le Provost GS; Todorov P; Baston E; Hickman E; Mahon T; Hassan N; Vuidepot A; Sami M; Cole DK; Jakobsen BK
Sci Rep; 2016 Jan; 6():18851. PubMed ID: 26758806
[TBL] [Abstract][Full Text] [Related]
32. TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential.
Poorebrahim M; Mohammadkhani N; Mahmoudi R; Gholizadeh M; Fakhr E; Cid-Arregui A
Cancer Gene Ther; 2021 Jun; 28(6):581-589. PubMed ID: 33654227
[TBL] [Abstract][Full Text] [Related]
33. Targeted elimination of prostate cancer by genetically directed human T lymphocytes.
Gade TP; Hassen W; Santos E; Gunset G; Saudemont A; Gong MC; Brentjens R; Zhong XS; Stephan M; Stefanski J; Lyddane C; Osborne JR; Buchanan IM; Hall SJ; Heston WD; Rivière I; Larson SM; Koutcher JA; Sadelain M
Cancer Res; 2005 Oct; 65(19):9080-8. PubMed ID: 16204083
[TBL] [Abstract][Full Text] [Related]
34. T Cell Receptor Engineered Lymphocytes for Cancer Therapy.
Rollins MR; Spartz EJ; Stromnes IM
Curr Protoc Immunol; 2020 Jun; 129(1):e97. PubMed ID: 32432843
[TBL] [Abstract][Full Text] [Related]
35. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.
Cho HI; Kim UH; Shin AR; Won JN; Lee HJ; Sohn HJ; Kim TG
Br J Cancer; 2018 Feb; 118(4):534-545. PubMed ID: 29360818
[TBL] [Abstract][Full Text] [Related]
36. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.
Chheda ZS; Kohanbash G; Okada K; Jahan N; Sidney J; Pecoraro M; Yang X; Carrera DA; Downey KM; Shrivastav S; Liu S; Lin Y; Lagisetti C; Chuntova P; Watchmaker PB; Mueller S; Pollack IF; Rajalingam R; Carcaboso AM; Mann M; Sette A; Garcia KC; Hou Y; Okada H
J Exp Med; 2018 Jan; 215(1):141-157. PubMed ID: 29203539
[TBL] [Abstract][Full Text] [Related]
37. Preventing tumor escape by targeting a post-proteasomal trimming independent epitope.
Textor A; Schmidt K; Kloetzel PM; Weißbrich B; Perez C; Charo J; Anders K; Sidney J; Sette A; Schumacher TN; Keller C; Busch DH; Seifert U; Blankenstein T
J Exp Med; 2016 Oct; 213(11):2333-2348. PubMed ID: 27697836
[TBL] [Abstract][Full Text] [Related]
38. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
[TBL] [Abstract][Full Text] [Related]
39. Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity.
Göbel C; Breitenbuecher F; Kalkavan H; Hähnel PS; Kasper S; Hoffarth S; Merches K; Schild H; Lang KS; Schuler M
Cell Death Dis; 2014 Dec; 5(12):e1568. PubMed ID: 25501829
[TBL] [Abstract][Full Text] [Related]
40. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
